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Accepted 18 June 2013Neuroendocrine tumors are more common in the female genital
tract than in the male genital tract, and most are uterine small cell
carcinomas or ovarian carcinoid tumors. Most ovarian tumors are
associated with surface epithelial tumors, SertolieLeydig cell tu-
mors, teratoma, small cell carcinoma, pulmonary-type and undif-
ferentiated carcinoma, and nonsmall cell lung cancer [1]. Large cell
neuroendocrine carcinoma (LCNEC) of the ovary is unusual and
deﬁned as an extremely malignant tumor with an aggressive lethal
outcome. For this original and updated review, we searched the
databases of PubMed Clinical Queries, MEDLINE, Cochrane Library
and UpToDate. We also hand-searched relevant journals and
reference lists of identiﬁed articles. The keywords used were
“ovary”, “pure LCNEC”, and “immunohistochemistry”. We found
that only 37 cases of ovarian tumor involving LCNEC associated
with surface epithelial stromal tumors and/or teratoma have been
reported to date [2e5]. In addition, seven cases of primary LCNEC of
the ovary without any associated component have been described
[2,3,6e8]. Herein, we present the case of a patient with stage IV
primary pure LCNEC of the ovary with liver metastasis and
carcinomatosis.
A 50-year-old married, Taiwanese female, G3P3, was referred by
a clinical oncologist for the evaluation of a pelvic mass. She denied
speciﬁc systemic disease, a gynecological history, and undergoing
major operations previously. She also denied any signiﬁcant
symptoms, such as compression sensation, lower abdominal pain,
or abnormal vaginal bleeding. Because of an increased abdominal
circumference and a palpable 20-cmmass in the abdomen that had
been present for 2 weeks, she was referred by a clinical oncologist
and underwent a suboptimal debulking operation with total
abdominal hysterectomy, bilateral salpingo-oophorectomy, partial* Corresponding author. Department of Obstetrics and Gynecology, Tri-Service
General Hospital, National Defense Medical Center, 5F, 325, Section 2, Cheng-
Gong Road, Nei-Hu District, Taipei 114, Taiwan.
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1028-4559/Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Publishedomentectomy, and appendectomy. Lymph node dissection was
omitted to avoid excessive bleeding, and liver palpation found
multiple metastases compatible with the previous computed
tomographic (CT) ﬁnding of liver metastases. The ﬁnal diagnosis
was LCNEC (Fig. 1) of the ovary (International Federation of Gyne-
cology and Obstetrics stage IV; American Joint Committee on
Cancer staging T3cN1M1). Brain CT and a bone scan for tumor
evaluation were negative. Postoperative adjuvant chemotherapy
with paclitaxel þ carboplatin was planned; however, she was
morbid with nausea, vomiting, anorexia, and general weakness
after the chemotherapy and refused further treatment. Although
the serum CA125 level dropped from 685.8 to 68.73 U/mL after
three cycles of chemotherapy, a newly developed nodular opacity
measuring approximately 2.3 cm in the right middle lung was
noted. Therefore, disease progression with pulmonary metastases
was suspected. Unfortunately, the patient died 3 months post-
surgery after sustaining intracranial hemorrhage following an
accidental fall-down injury.
The gross pathology examination revealed that the uterus was
1313 6 cm in sizewithmultiple myomas and adenomyosis. The
left ovary showed a very large fragile mass measuring approxi-
mately 25 cm in diameter with pelvic wall and intestinal invasion.
The left fallopian tube, parametrium, omentum, and surface of the
appendix also showed tumor invasion.
Histologically, the predominant pattern was pleomorphic with
hyperchromatic tumor cells arranged in trabecular (Fig. 2A), solid
(Fig. 2B), and rosette-like growth patterns (Fig. 2C) with high
mitotic activity (Fig. 2D; >20 ﬁgures/10 high-power ﬁelds) and foci
of spotty tumor necrosis.
The tumor cells were positive for chromogranin A (Fig. 3A),
vimentin (Fig. 3B), CD56 (Fig. 3C), and neuron speciﬁc enolase
(NSE) (Fig. 3D) but negative for CK7 and CK20. Diagnosis of LCNEC
of the ovary was made based on clinical data, histopathological
features, and immunoproﬁles.
Primary LCNEC of the ovary is a rare tumor and is now included
in the World Health Organization (WHO) tumor classiﬁcation. Ac-
cording to the WHO, this tumor is synonymous with “undifferen-
tiated carcinoma of nonsmall cell neuroendocrine type” and is
deﬁned as “a malignant tumor composed of large cells that show
neuroendocrine differentiation” [9]. Although four cases of primary
pure LCNEC of the ovary have been described, 30 published cases
have been associated with ovarian epithelial tumors or germ cellby Elsevier Taiwan LLC. All rights reserved.
Fig. 1. The main tumor arising from the left ovary showed a very large fragile mass that
measured approximately 25 cm in diameter with a bizarre appearance.
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LCNEC most likely arises from the neuroendocrine cells present on
surface epithelial stromal tumors or teratoma [10]. One theory on
the origin of primary pure neuroendocrine tumors suggests the
existence of a primitive endodermal cell that is capable of differ-
entiating into other cell types or the activation of genes promoting
neuroendocrine differentiation fromnon-neuroendocrine cells [11].
When making the diagnosis, LCNEC should be distinguished
from some other tumors such as primary or metastatic carcinoid
tumor, small cell carcinoma of the pulmonary or hypercalcemicFig. 2. Histological examination results indicated that the tumor was a large cell neuroendoc
(B) solid, and (C) rosette-like growth patterns. High-power view of the neuroendocrine c
chromatin and inconspicuous nucleoli were present with numerous mitoses.type, metastatic neuroendocrine carcinoma, anaplastic carcinoma
arising in mucinous tumor, or primitive neuroectodermal tumor
[12]. Primary and metastatic carcinoid tumors can be distinguished
from LCNEC by their low mitotic activity, cytological uniformity,
organized architectural patterns, and absence of necrosis [5].
Microscopically, primary LCNEC is characterized by large tumor
cells, speciﬁcally oval to round in shape, which are usually arranged
in solid nests, sheets, or a trabecular pattern. The glandular or
cribriform formation is less frequently observed. The differential
diagnosis and pathological structures are presented in Table 1
[5,12].
Histologically, the tumor has large vesicular nucleoli or coarse
chromatin without predominant nucleoli and sometimes has
extensive necrosis and numerous mitoses [7,10]. In our case, the
pleomorphic and hyperchromatic tumor cells were arranged in
trabecular, solid, and rosette-like growth patterns with highmitotic
activity and foci of spotty tumor necrosis.
Neuroendocrine differentiation can be conﬁrmed by immuno-
histochemical analysis due to the neuroendocrine nature of the cell,
as these cells express at least one neuroendocrine marker (e.g.,
CD56, chromogranin A, synaptophysin, or NSE) [2,10]. In the case
presented, the immunohistochemical stains showed that the tumor
cells were positive for CD56, chromogranin, and NSE but negative
for the epithelial markers CK7 and CK20. Thus, this case fulﬁlls the
structure and immunohistochemical criteria for a primary pure
LCNEC of the ovary.
Because of the rarity of this condition, only limited data are
available to guide the treatment of patients with LCNEC of the
ovary. Most patients undergo primary surgery to obtain the
deﬁnitive tissue diagnosis and staging and a tumor debulking
operation. Follow-up study was available in 38 reported cases
(including this one), and 30 patients received chemotherapy.
Various combinations of chemotherapy had been chosen, includingrine carcinoma. Low-power view of neuroendocrine carcinoma showing (A) trabecular,
arcinoma showing variable tumor cells with oval nuclei. (D) Fine, evenly distributed
Fig. 3. Immunoperoxidase stains of the large cell neuroendocrine carcinoma were positive for (A) chromogranin A, (B) vimentin, (C) CD56, (D) and NSE.
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cisplatin; or paclitaxel and carboplatin protocols [3]. Veras et al
reported that even stage III or IV cases with standard surgery that
was followed by adjuvant platinum-based chemotherapy had
prognosis similar to that of the early stage cases [10]. Although the
optimal chemotherapy regimen for LCNEC has not yet been
established, platinum-based chemotherapy and paclitax-
elecarboplatin-based chemotherapy have been suggested [5]. In
the present case, three cycles of paclitaxel (175 mg/
M2) þ carboplatin (area under the concentration curve: 5) wereTable 1
Pathological structures and clinical abnormalities of the neuroendocrine tumor of
the ovary.
Classiﬁcation Pathological structures and
clinical abnormalities
Primary large cell
neuroendocrine
carcinoma
1. Large to intermediate in size
2. Oval to round in shape
3. Low nucleus-to-cytoplasm ratio
4. Oval to round in shape
5. Arranged in solid nests, sheets,
or a trabecular pattern
Primary or metastatic
carcinoid tumor
1. Low mitotic activity
2. Cytological uniformity
3. Organized architectural patterns
4. Absence of necrosis
Small cell carcinoma
of pulmonary type
1. Smaller size
2. Less intense immunohistochemical
reaction for CK and chromogranin
Small cell carcinoma
of hypercalcemic type
1. Large cells
2. Pale intracytoplasmic hyaline globules
3. Follicle-like spaces
4. Hypercalcemia
Metastatic neuroendocrine
carcinoma
1. Bilateral involvement
2. Multinodular growth and vascular invasion
3. Not admixed with ovarian surface
epithelial tumorsadministered every third week. In addition, in two cases of LCNEC
that included brain metastasis, both tumor resection and adjuvant
radiotherapy resulted in patient survival [2]. The effects of radiation
therapy have not been proven yet, but we believe that the combi-
nation of chemotherapy with aggressive surgery and adjuvant ra-
diation therapy should be considered as a possible treatment
strategy.
In conclusion, LCNEC of the ovary is unusual and deﬁned as an
extremely malignant tumor. Early diagnosis is difﬁcult, and even at
an early stage, the prognosis is poor. Only 30 cases have been re-
ported, and it is typically associated with surface epithelial tumors
or germ cell tumors. On rare occasions, it may occur in a pure form,
with only three cases reporting pure LCNEC at the time of this
writing. The tumor has an aggressive lethal outcome, and many
patients die within 1e3 years. Although this case was stage IV with
liver metastasis and carcinomatosis, we administered adjuvant
chemotherapy with paclitaxelþ carboplatin. However, there are no
strong conclusions on the prognosis at this stage with the use of
platinum-based chemotherapy.
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